Arrowhead Pharmaceuticals (ARWR) Other Working Capital Changes (2014 - 2026)

Arrowhead Pharmaceuticals (ARWR) has 10 years of Other Working Capital Changes data on file, last reported at -$2.4 million in Q1 2026.

• Quarterly Other Working Capital Changes fell 105.66% year-over-year to -$2.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$43.3 million (down 197.36% YoY) and the FY2025 annual result came in at $2.4 million, up 99.92% from the prior year.
• Other Working Capital Changes eased to -$4.8 million in Q1 2026, from $13.2 million in the prior quarter.
• In the past five years, Other Working Capital Changes ranged from a high of $159.7 million in Q3 2023 to a low of -$114.3 million in Q2 2023.
• A 5-year average of -$5.0 million and a median of -$20.3 million in 2025 frame the typical range for Other Working Capital Changes.
• The widest YoY moves for Other Working Capital Changes: up 2173.07% in 2025, down 15025.61% in 2025.
• Tracing ARWR's Other Working Capital Changes over 5 years: stood at -$23.0 million in 2022, then soared by 795.13% to $159.7 million in 2023, then tumbled by 99.25% to $1.2 million in 2024, then plunged by 98.0% to $24000.0 in 2025, then plunged by 10295.83% to -$2.4 million in 2026.
• The last three Other Working Capital Changes figures came in at -$2.4 million (Q1 2026), $24000.0 (Q4 2025), and -$20.6 million (Q3 2025), per Business Quant data.